Exact Mass: 379.11774060000005
Exact Mass Matches: 379.11774060000005
Found 78 metabolites which its exact mass value is equals to given mass value 379.11774060000005,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Hyaluronan biosynthesis, precursor 1
This compound belongs to the family of N-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moeity in which the oxygen atom is replaced by an n-acyl group.
2H-1-Benzopyran-2-one, 7-[[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]oxy]-4-methyl-
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
Cyclohexanecarboxamide, N-(2-((ethylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-
C15H20F3N3O3S (379.11774060000005)
2-deoxy-N-glycoloyl-9-O-lactoyl-2,3-didehydroneuraminic acid
Hymecromone, O-(2-Acetamido-2-deoxy-beta-D-glucopyranoside)
Coumarins
Cys Gly Asn Ser
C12H21N5O7S (379.11616360000005)
Cys Gly Ser Asn
C12H21N5O7S (379.11616360000005)
Cys Asn Gly Ser
C12H21N5O7S (379.11616360000005)
Cys Asn Ser Gly
C12H21N5O7S (379.11616360000005)
Cys Ser Gly Asn
C12H21N5O7S (379.11616360000005)
Cys Ser Asn Gly
C12H21N5O7S (379.11616360000005)
Gly Cys Asn Ser
C12H21N5O7S (379.11616360000005)
Gly Cys Ser Asn
C12H21N5O7S (379.11616360000005)
Gly Asn Cys Ser
C12H21N5O7S (379.11616360000005)
Gly Asn Ser Cys
C12H21N5O7S (379.11616360000005)
Gly Ser Cys Asn
C12H21N5O7S (379.11616360000005)
Gly Ser Asn Cys
C12H21N5O7S (379.11616360000005)
Asn Cys Gly Ser
C12H21N5O7S (379.11616360000005)
Asn Cys Ser Gly
C12H21N5O7S (379.11616360000005)
Asn Gly Cys Ser
C12H21N5O7S (379.11616360000005)
Asn Gly Ser Cys
C12H21N5O7S (379.11616360000005)
Asn Ser Cys Gly
C12H21N5O7S (379.11616360000005)
Asn Ser Gly Cys
C12H21N5O7S (379.11616360000005)
Ser Cys Gly Asn
C12H21N5O7S (379.11616360000005)
Ser Cys Asn Gly
C12H21N5O7S (379.11616360000005)
Ser Gly Cys Asn
C12H21N5O7S (379.11616360000005)
Ser Gly Asn Cys
C12H21N5O7S (379.11616360000005)
Ser Asn Cys Gly
C12H21N5O7S (379.11616360000005)
Ser Asn Gly Cys
C12H21N5O7S (379.11616360000005)
Chondroitin
4-(4-fluorobenzoyl)piperidine p-toluenesulfonate
C19H22FNO4S (379.12535040000006)
Urea, N-(4-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]- (9CI)
4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-2-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-6-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
4-Methylumbelliferyl-N-acetyl-beta-D-galactosaminide hydrate
6-Oxo-2-phenyl-5-[[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidineacetic acid
(1-methylpiperidin-4-yl) 2-chloro-2,2-diphenylacetate,hydrochloride
4,11-diamino-2-(3-methoxypropyl)-1H-Naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid
(3-Chloro-5-trifluoroMethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl)-carbaMic acid tert-butyl ester
4-Methylumbelliferyl 2-amino-2-deoxy-a-D-glucopyranoside
5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
C19H22ClNO5 (379.11864320000007)
Fuzapladib
C15H20F3N3O3S (379.11774060000005)
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2144 - Endothelial-Specific Integrin/Survival Signaling Inhibitor D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors C308 - Immunotherapeutic Agent > C574 - Immunosuppressant Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
3-[Isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid
C22H21NO3S (379.1242076000001)
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc
An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
(2R,3R,4S)-2-[(2R,3R,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N-(4-fluorophenyl)urea
4-(2,5-dimethoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione
2-(5-chloro-2-pyridinyl)-3-(4-ethoxyanilino)-3H-isoindol-1-one
(5E)-3-[(2-fluorophenyl)methyl]-5-[[1-(4-fluorophenyl)pyrrol-2-yl]methylidene]imidazolidine-2,4-dione
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide
N-(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-bis(aminium)
3-(4-Deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose
N-acetyl-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-D-galactosamine
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
3-(4-deoxy-beta-D-gluc-4-enosyluronic acid)-N-acetyl-D-glucosamine
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
3-{1-[3,6-dihydroxy-5-(methanesulfinylmethyl)-2,5-dihydropyrazin-2-yl]ethyl}-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
3-hydroxy-4,5-dimethoxy-6-[2-(5-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
(4s,5r,6r)-6-{[(3r,4r,5r,6r)-2,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylic acid
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
3-hydroxy-4,5-dimethoxy-6-[2-(4-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)
3-hydroxy-4,5-dimethoxy-6-[2-(3-methyl-4-oxopentyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)